Ollin Biosciences to Participate in Two Upcoming Investor Conferences

Audio By Carbonatix

AUSTIN, Texas--(BUSINESS WIRE)--Apr 8, 2026--

Ollin Biosciences, Inc. (Ollin), a clinical-stage biotech advancing best-in-disease therapies for vision-threatening diseases, today announced that Company management will participate in the private company tracks of two upcoming investor conferences.

Piper Sandler Biopharma Symposium

1x1 Meetings: Wednesday, April 15, 2026
Location: Boston, MA

UBS Private Biotech Summit

1x1 Meetings: Monday, May 18, 2026
Location: New York, NY

About Ollin Biosciences

Established in 2023, Ollin Biosciences TM is a clinical-stage biopharmaceutical company dedicated to acquiring and developing best-in-disease therapies for vision-threatening diseases. With a differentiated pipeline, world-class team, and strong investor syndicate, Ollin is redefining what’s possible in ophthalmology. For more information, please visit us at www.ollin.bio and follow us on LinkedIn and X.

View source version on businesswire.com:https://www.businesswire.com/news/home/20260408503553/en/

CONTACT: Media & Investors:

Katie Engleman

1AB

[email protected]

KEYWORD: TEXAS UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: BIOTECHNOLOGY GENERAL HEALTH OPTICAL HEALTH

SOURCE: Ollin Biosciences, Inc.

Copyright Business Wire 2026.

PUB: 04/08/2026 08:00 AM/DISC: 04/08/2026 08:00 AM

http://www.businesswire.com/news/home/20260408503553/en